KMTS Kestra Medical Technologies, Ltd.
USHealthcareAs of 2026-07-09 16:00
Why KMTS matters now
Kestra Medical Technologies, Ltd. (KMTS) is a US stock in Healthcare. The latest InvestLog snapshot shows $26.69 with -0.41% on the session and $1.56B in market capitalization; recent performance reads 1-month +0.66% and YTD -24.85%.
The latest financial table shown here is Q3 2026, with revenue of $24.6M, net income of $-34.2M, and EPS of $-0.61. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.3%.
The latest indexable market news headline is "Kestra Medical Technologies to Report Fourth Quarter Fiscal 2026 Financial Results on July 14" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $24.00; recent insider activity includes Webster Brian Daniel filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.66
P/S
13.90
EV/EBITDA
-6.85
DCF Value
$4.28
FCF Yield
-10.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
48.8%
Operating Margin
-171.5%
Net Margin
-173.0%
ROE
-68.8%
ROA
-38.2%
ROIC
-42.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $24.6M | $-34.2M | $-0.61 |
| Q2 2026 | $22.6M | $-32.8M | $-0.64 |
| Q1 2026 | $19.4M | $-25.8M | $-0.50 |
| Q4 2025 | $17.2M | $-52.1M | $-2.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$24.00
Target (Median)
$24.00
Target Range
$24.00 - $24.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
0.83
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.